Powering the next generation in bioelectric medicine with Nanosecond Pulsed Field Ablation technology.
Pulse Biosciences pioneers in the research, design and production of our patented Nanosecond Pulsed Field Ablation™ (nsPFA™) technology for use in high impact areas of healthcare. We are currently focused on applying this technology within cardiology. We believe there may be several applications in cardiology for nsPFA, including atrial fibrillation.
Nanosecond Pulsed Field Ablation (nsPFA) energy is a novel technology that has the potential to not only help patients with atrial fibrillation, but patients across multiple different therapy areas.
Pulse Biosciences announces poster presentation at the 2023 AF Symposium describing the novel use of Nanosecond Pulsed Field Ablation (nsPFA) technology in cardiac ablation for the treatment of arrhythmias. View press release.
Our proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. nsPFA energy is delivered from the powerful and versatile nsPFA™ generator platform. The nsPFA platform was developed to be capable of connecting to multiple types of applicators from superficial to surgical to catheter-based therapies. Our system has already been used to treat over 6,000 patients safely and effectively outside of Cardiology.
These ultrafast electrical energy pulses have pulse durations from billionths up to a millionth of a second. When applied to targeted tissue, nsPFA energy pulses enter cells and alter the function of the internal cellular organelles, including the mitochondria and endoplasmic reticulum. The cascade of intracellular disruption leads to regulated cell death (RCD). RCD is a process exhibited by cells in the human body when they undergo stress and are unable to restore cellular homeostasis.
Pulse Biosciences has brought to market the first commercial product to harness the distinctive advantages of nsPFA technology.
Mechanism of Action
- Non-thermal modality that delivers nanosecond duration pulses of electrical energy
- Unlike thermal technologies, nsPFA™ energy directly impacts cellular structures while sparing non cellular tissue
- nsPFA™ energy pulses initiates nanopores in cellular membranes that allow ions, such as calcium, to move within the cell
- Triggers a cascade of intracellular disruption that stresses vital cell organelles
- Breakdown of vital cell organelles leads to regulated cell death (RCD)
Pulse Biosciences is the inventor and sole proprietor of Nanosecond Pulsed Field Ablation™ (nsPFA™) technology. We are committed to health innovation that has the potential to improve and extend the lives of patients. Our proprietary Nanosecond Pulsed Field Ablation technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue.
The people at Pulse Biosciences are some of the top experts in pulsed electric field technologies and have a broad range of engineering expertise across multiple medical device domains and will utilize nsPFA™ technology to treat a variety of applications for which an optimal solution remains unfulfilled.
We have a deep and broad IP portfolio with over 130 issued patents globally owned and licensed. With this growing patent portfolio surrounding our innovative technology, Pulse Biosciences seeks to aggressively realize the potential of Nanosecond Pulsed Field Ablation technology by building a rich pipeline of transformative commercial applications.
Pulse Biosciences, Inc.
3957 Point Eden Way
Hayward, California 94545
- +1 833.257.3393